AU Patent

AU2017350852A1 — Treatment of prurigo nodularis

Assigned to Trevi Therapeutics Inc · Expires 2019-04-11 · 7y expired

What this patent protects

The present invention relates to methods for treating prurigo nodularis with anti-pruritic compositions, wherein the method provides a therapeutic effect in a patient.

USPTO Abstract

The present invention relates to methods for treating prurigo nodularis with anti-pruritic compositions, wherein the method provides a therapeutic effect in a patient.

Drugs covered by this patent

diclofenac-potassium (DICLOFENAC POTASSIUM)

Patent Metadata

Patent number: AU2017350852A1
Jurisdiction: AU
Classification: —
Expires: 2019-04-11
Drug substance claim: No
Drug product claim: No
Assignee: Trevi Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.